Hovione expansion provides integrated full-service solution
Additional capacity expansion across several of the company's sites also strengthens the company's global market leadership in spray drying.
Hovione has announced recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey, with the aim to increase capacity in existing technologies, such as spray drying and to grow in new areas of business to support client demand.
The capacity expansion program, which started in 2016, will continue during the next 5 years. The first 2 years saw Hovione relocate its development services to a new 7000 m2 centre in Lisbon, 15 minutes away from the Loures manufacturing site. The new Lisbon site is fully equipped to handle potent and highly potent compounds, and hosts 200 scientists specialising in chemistry, particle engineering, formulation and analytical development.
During this period, the Loures site expanded its drug substance reaction vessel capacity with a small-scale production area and a new pilot plant, totalling an extra 30 m3 of capacity. In addition, one pilot and two large-scale spray dryers were installed at the site and started the operation of a new drug product centre equipped with oral dosage form and inhalation manufacturing capabilities.
During the same time, Hovione doubled the size of its development and manufacturing operations in the New Jersey site, providing it with a full range of capabilities, from chemical and analytical development, through spray drying to formulation. The site now hosts 14 m3 of reaction vessel capacity with four independent trains, a pilot and a large scale spray dryer, and a continuous tableting unit.
At the Cork site, Hovione is reinstating and renewing a production building with 157 m3 of chemical synthesis capacity devoted to contract manufacturing. About half of this capacity will be ready for operation by May 2018.
During the next 3 years, Hovione will add to the Loures site a new chemical synthesis and spray dryer building for contract manufacturing, with a total area of 4,200 m2 for 165 m3 of reaction vessel capacity and two large spray drying units, new formulation facilities, which will enable the production of bigger batch sizes, and a new building that will host an additional 1200 m2 of analytical laboratories.
This investment is being paired with recruiting and training new staff, as illustrated by the company's 39% headcount growth in the last 2 years.
“This addition in capacity expansion will secure our growth and ensure that we continue to provide a truly integrated full-service solution to our customers, as well as showing Hovione’s strategy and commitment to further strengthen its global market leadership in spray drying,” said Frédéric Kahn, Vice-President Marketing & Sales.
“This capacity expansion plan is far more than a matter of production capacity solely. It aims to reorganize sites with new buildings, renew existing facilities and give operations the most advanced equipment in the market, to provide our customers and team members with the technology and the capacity they need to grow in a sustainable way. It is a significant effort and commitment from Hovione to stay ahead of and prepare for future demand.” said Nuno Almeida, Vice-President of Engineering.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance